A Phase Ib Double-Blind Randomized Placebo Controlled Age-Deescalating Trial of Two Virosome Formulated Anti-Malaria Vaccine Components (PEV 301 and PEV 302) Administered in Combination to Healthy Semi-Immune Tanzanian Volunteers.

Trial Profile

A Phase Ib Double-Blind Randomized Placebo Controlled Age-Deescalating Trial of Two Virosome Formulated Anti-Malaria Vaccine Components (PEV 301 and PEV 302) Administered in Combination to Healthy Semi-Immune Tanzanian Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Nov 2014

At a glance

  • Drugs Malaria vaccine (Primary) ; Influenza virus vaccine
  • Indications Falciparum malaria; Malaria
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 18 Nov 2014 Results published in a Mymetics Corporation media release.
    • 01 May 2009 Additional lead trial centre identified as reported by ClinicalTrials.gov record.
    • 09 Jan 2009 Actual start date (Dec 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top